INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 170 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2014. The put-call ratio across all filers is 2.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2016 | $626,000 | +100.6% | 3,805 | +81.9% | 0.21% | +93.6% |
Q4 2015 | $312,000 | +75.3% | 2,092 | +94.6% | 0.11% | +89.7% |
Q3 2015 | $178,000 | -18.0% | 1,075 | +19.8% | 0.06% | -20.5% |
Q2 2015 | $217,000 | -65.9% | 897 | -66.6% | 0.07% | -66.0% |
Q3 2014 | $636,000 | +63.1% | 2,689 | +63.1% | 0.22% | +77.7% |
Q2 2014 | $390,000 | +87.5% | 1,649 | +161.3% | 0.12% | +80.6% |
Q1 2014 | $208,000 | – | 631 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |